GlaxoSmithKline plc (LON:GSK) received a GBX 1,700 ($21.51) price target from research analysts at Morgan Stanley in a note issued to investors on Friday, May 12th. The brokerage currently has a “neutral” rating on the stock. Morgan Stanley’s target price points to a potential upside of 0.89% from the stock’s current price.
GSK has been the subject of several other reports. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline plc in a report on Monday, January 30th. Liberum Capital reaffirmed a “buy” rating and issued a GBX 1,900 ($24.04) price target on shares of GlaxoSmithKline plc in a report on Thursday, March 9th. Goldman Sachs Group, Inc. (The) lifted their price target on shares of GlaxoSmithKline plc from GBX 1,800 ($22.77) to GBX 1,850 ($23.40) and gave the company a “buy” rating in a report on Tuesday, January 24th. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline plc in a report on Thursday, January 26th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and issued a GBX 1,750 ($22.14) price target on shares of GlaxoSmithKline plc in a report on Thursday, February 9th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. GlaxoSmithKline plc presently has a consensus rating of “Hold” and an average target price of GBX 1,745.17 ($22.08).
Shares of GlaxoSmithKline plc (GSK) traded up 0.06% during midday trading on Friday, hitting GBX 1685.00. 19,969,256 shares of the stock traded hands. GlaxoSmithKline plc has a one year low of GBX 1,363.00 and a one year high of GBX 1,745.56. The stock’s market cap is GBX 82.33 billion. The firm has a 50-day moving average price of GBX 1,647.07 and a 200 day moving average price of GBX 1,604.10.
The firm also recently announced a dividend, which will be paid on Thursday, July 13th. Investors of record on Thursday, May 11th will be issued a GBX 19 ($0.24) dividend. The ex-dividend date is Thursday, May 11th. This represents a dividend yield of 1.21%.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/06/17/morgan-stanley-analysts-give-glaxosmithkline-plc-gsk-a-gbx-1700-price-target-updated-updated-updated.html.
In other GlaxoSmithKline plc news, insider Vivienne Cox bought 335 shares of the company’s stock in a transaction that occurred on Wednesday, April 26th. The shares were acquired at an average cost of GBX 1,583 ($20.03) per share, for a total transaction of £5,303.05 ($6,708.48). Also, insider Emma Walmsley bought 83 shares of the company’s stock in a transaction that occurred on Tuesday, April 18th. The stock was acquired at an average price of GBX 1,647 ($20.83) per share, for a total transaction of £1,367.01 ($1,729.30). Insiders purchased a total of 662 shares of company stock worth $1,067,188 over the last quarter.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.